Adding to existing literature showing the efficacy of GLP-1 RAs, such as exenatide, in lowering levels of CRP, we show for the first time that these effects are not age- nor comorbidity- dependent, pointing to the potential scalability and widespread suitability of repurposing of this diabetic drug in lowering systemic inflammation associated with dementia risk. This evidence concerns the gene CRP and dementia.